We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00303407
Recruitment Status : Terminated
First Posted : March 16, 2006
Last Update Posted : March 16, 2006
Information provided by:
University Hospital, Geneva

Brief Summary:
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care

Condition or disease Intervention/treatment Phase
Cancer Venous Thromboembolism Drug: nadroparin Phase 4

Study Type : Observational
Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective
Study Start Date : January 2001
Estimated Study Completion Date : July 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Palliative Care
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Cancer patients in palliative care
  • Patients fully informed about their condition
  • Signed informed consent
  • No exclusion criteria

Exclusion Criteria:

  • Absence of advanced cancer
  • Cancer previously cured
  • Venous thromboembolism diagnosed within 6 months prior to inclusion
  • Absence of discerning capacity
  • Active anti-thrombotic treatment with heparins or coumarines
  • Thrombocytopenia <50G/l
  • PTT >45sec
  • TP<35%
  • Active bleeding
  • Renal failure <20ml/min
  • Past history of heparin-induced thrombocytopenia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00303407

Center of Continuous Care, chemin de la Savonnière
Collonge-Bellerive (Geneva), Geneva, Switzerland, 1245
Sponsors and Collaborators
University Hospital, Geneva
Principal Investigator: Catherine Weber, MD Center of Continuous Care, chemin de la Savonnière 11, CH-1245 Collonge-Bellerive

ClinicalTrials.gov Identifier: NCT00303407     History of Changes
Other Study ID Numbers: SPOT 99/54
First Posted: March 16, 2006    Key Record Dates
Last Update Posted: March 16, 2006
Last Verified: December 2005

Additional relevant MeSH terms:
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action